184 related articles for article (PubMed ID: 17049687)
41. Differential immunogenicity of Vibrio cholerae O139 variants expressing different combinations of naturally occurring and atypical forms of the serogroup polysaccharide.
Attridge SR; Wallerström G; Li BL; Morona R; Holmgren J
Vaccine; 2009 Feb; 27(7):1055-61. PubMed ID: 19100303
[TBL] [Abstract][Full Text] [Related]
42. [The oral cholera vaccine project; the first 3 years of field work in Bangladesh].
van Loon FP
Ned Tijdschr Geneeskd; 1991 Jan; 135(3):87-9. PubMed ID: 1996165
[No Abstract] [Full Text] [Related]
43. Cholera vaccines for the developing world.
Lopez AL; Clemens JD; Deen J; Jodar L
Hum Vaccin; 2008; 4(2):165-9. PubMed ID: 18414029
[TBL] [Abstract][Full Text] [Related]
44. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice.
Pérez JL; Acevedo R; Callicó A; Fernández Y; Cedré B; Año G; González L; Falero G; Talavera A; Pérez O; García L
Vaccine; 2009 Jan; 27(2):205-12. PubMed ID: 18996426
[TBL] [Abstract][Full Text] [Related]
45. [Complex morphological approach to assessment of protective properties of preparations for cholera specific prophylaxis].
Bugorkova SA; Zadumina SIu; Bugorkova TV; Lotsmanova EIu; Kravtsov AL; Shchukovskaia TN; Kutyrev VV
Zh Mikrobiol Epidemiol Immunobiol; 2008; (1):31-4. PubMed ID: 18368749
[TBL] [Abstract][Full Text] [Related]
46. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae.
Nygren E; Holmgren J; Attridge SR
Vaccine; 2008 Dec; 26(52):6784-90. PubMed ID: 18951939
[TBL] [Abstract][Full Text] [Related]
47. Live attenuated oral cholera vaccines.
Ryan ET; Calderwood SB; Qadri F
Expert Rev Vaccines; 2006 Aug; 5(4):483-94. PubMed ID: 16989629
[TBL] [Abstract][Full Text] [Related]
48. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
Viret JF; Dietrich G; Favre D
Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
[TBL] [Abstract][Full Text] [Related]
49. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding.
Ahmed T; Svennerholm AM; Al Tarique A; Sultana GN; Qadri F
Vaccine; 2009 Feb; 27(9):1433-9. PubMed ID: 19146904
[TBL] [Abstract][Full Text] [Related]
50. Experimental heat-inactivated cholera vaccine for intradermal use.
Ciufecu C; Năcescu N; Chirescu N; Israil A; Stefănescu C
Arch Roum Pathol Exp Microbiol; 1983; 42(1):59-64. PubMed ID: 6336507
[No Abstract] [Full Text] [Related]
51. Crossed immunoelectrophoretic analysis of antigenic composition of B-subunit/whole-cell and whole-cell only killed oral cholera vaccines.
Ciznár I; Ahsan CR; Rahman A; Shahabuddin M; Bartková G; Clemens JD; Sack DA
Vaccine; 1992; 10(9):591-6. PubMed ID: 1502836
[TBL] [Abstract][Full Text] [Related]
52. [Orovaccine--cholera, a new inactivated oral vaccine].
Thilo W; Oberdoerster F; Morgenstern H; Seifert H
Dtsch Gesundheitsw; 1972 Oct; 27(40):1918-9. PubMed ID: 4642343
[No Abstract] [Full Text] [Related]
53. Use of oral cholera vaccines in an outbreak in Vietnam: a case control study.
Anh DD; Lopez AL; Thiem VD; Grahek SL; Duong TN; Park JK; Kwon HJ; Favorov M; Hien NT; Clemens JD
PLoS Negl Trop Dis; 2011 Jan; 5(1):e1006. PubMed ID: 21283616
[TBL] [Abstract][Full Text] [Related]
54. A Vibrio cholerae serogroup O1 vaccine candidate against CTX ET Phi infection.
Yan M; Liu G; Diao B; Qiu H; Zhang L; Liang W; Gao S; Kan B
Vaccine; 2007 May; 25(20):4046-55. PubMed ID: 17428586
[TBL] [Abstract][Full Text] [Related]
55. Oral cholera vaccines containing B-subunit-killed whole cells and killed whole cells only. II. Field evaluation of cross-protection against other members of the Vibrionaceae family.
Clemens JD; Harris JR; Kay BA; Chakraborty J; Sack DA; Ansaruzzaman M; Rahman R; Stanton BF; Khan MU; Khan MR
Vaccine; 1989 Apr; 7(2):117-20. PubMed ID: 2665350
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical, histological and ultrastructural evaluation of protection provided by cholera vaccine against V. cholerae O139.
Murugaiah C; Nik Mohd Noor NZ; Al-Talib H; Mustafa S; Manickam R; Pattabhiraman L
Microb Pathog; 2020 Mar; 140():103964. PubMed ID: 31904450
[TBL] [Abstract][Full Text] [Related]
57. A new inactivated oral cholera vaccine.
Oberdoerster F; Thilo W
Acta Microbiol Acad Sci Hung; 1974; 21(1-2):213-5. PubMed ID: 4440525
[No Abstract] [Full Text] [Related]
58. Can oral cholera vaccination play a role in controlling a cholera outbreak?
Calain P; Chaine JP; Johnson E; Hawley ML; O'Leary MJ; Oshitani H; Chaignat CL
Vaccine; 2004 Jun; 22(19):2444-51. PubMed ID: 15193408
[TBL] [Abstract][Full Text] [Related]
59. [Selection of attenuated Vibrio cholerae strains to obtain oral attenuated candidate vaccines against cholera].
María García H; Año G; Cedré B; Valmaseda T; Maestre JL; Díaz M; Mirabal M; Talavera A; García L
Rev Cubana Med Trop; 2005; 57(2):92-104. PubMed ID: 17966578
[TBL] [Abstract][Full Text] [Related]
60. Surveillance of vibriophages reveals their role as biomonitoring agents in Kolkata.
Das M; Bhowmick TS; Nandy RK; Nair GB; Sarkar BL
FEMS Microbiol Ecol; 2009 Mar; 67(3):502-10. PubMed ID: 19220862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
